AndroGel Safety in Young Adults (Ages 18, 29): What You Need to Know Before Starting

Does AndroGel Work for Young Men With Hypogonadism?

AndroGel raises serum testosterone into the normal adult range reliably in men of any age when used as directed. The T-Trials (N=790 men, though enrolled men aged 65 and older) confirmed that once-daily topical testosterone application normalized serum T levels, demonstrating the pharmacokinetic consistency of this delivery method [1]. Younger men in their 20s absorb percutaneous testosterone comparably, and most reach target serum levels within two weeks of dose optimization.

The FDA approved testosterone gel for male hypogonadism based on the criterion that two morning serum testosterone measurements fall below 300 ng/dL, paired with one or more clinical symptoms such as reduced libido, fatigue, or impaired erections [2]. Young adult men who meet that threshold carry the same clinical indication as older men. The difference lies in how long they will be exposed to exogenous testosterone and what physiological processes remain in progress during that exposure.

Hypogonadism in men under 30 is less common than in older populations, but it occurs. Secondary hypogonadism from causes such as Kallmann syndrome, pituitary adenoma, or prior opioid use is among the more frequent presentations in this age group [3]. Primary hypogonadism from Klinefelter syndrome (47,XXY) affects roughly 1 in 650 male births and often becomes clinically apparent in the late teens or early 20s [4]. A thorough diagnostic workup, including LH, FSH, prolactin, and morning total testosterone on two separate days, should always precede treatment.

Fertility: The Most Consequential Safety Concern for Men Under 30

Exogenous testosterone suppresses sperm production. This is not a rare side effect, it is the predictable result of HPG axis suppression. AndroGel raises circulating testosterone, which feeds back negatively on the hypothalamus and pituitary, reducing LH and FSH secretion within days to weeks [5]. Without LH stimulation, intratesticular testosterone (which must be 50 to 100 times higher than serum T to support spermatogenesis) collapses. Sperm counts fall to azoospermic or severely oligospermic levels in approximately 70% of men within three to six months of continuous testosterone therapy [6].

Recovery of spermatogenesis after stopping testosterone is variable and not guaranteed. A Cochrane-supported meta-analysis of male hormonal contraception studies found that roughly 5 to 10% of men did not recover sperm counts to the fertile range within two years of cessation [7]. For a 22-year-old man who may want children in the next five to ten years, that probability warrants a direct conversation before the first prescription is written.

The American Urological Association and the Endocrine Society both recommend discussing fertility plans with all hypogonadal men before initiating testosterone therapy [8]. Men who want to preserve future fertility have two evidence-based alternatives to AndroGel:

• hCG monotherapy (500, 1 to 000 IU subcutaneously three times per week) stimulates Leydig cells directly, raising intratesticular testosterone without suppressing the HPG axis.
• hCG plus recombinant FSH for men with secondary hypogonadism who need both Leydig cell and Sertoli cell stimulation to achieve spermatogenesis [9].

Sperm banking before starting any testosterone therapy is a low-cost, high-certainty safeguard. The American Society for Reproductive Medicine recommends cryopreservation as an option for any man starting a treatment known to impair fertility [10].

Bone Safety: Growth Plates Must Be Closed

Testosterone accelerates bone maturation by aromatizing to estradiol, which drives epiphyseal fusion. In boys who have not completed pubertal growth, exogenous testosterone can close growth plates prematurely and reduce final adult height permanently [11]. This concern is most relevant for 18- and 19-year-old patients who began puberty late or who have constitutional delay of growth and puberty.

Before prescribing AndroGel to any patient under 21, a bone age X-ray (typically the left hand and wrist, read against the Greulich-Pyle atlas) confirms that growth plates are closed. Most clinicians order this routinely for anyone 18, 20. Bone age equal to or greater than 17 years by radiographic standards is generally accepted as indicating closed plates, though individual variation exists [12].

On the positive side, young hypogonadal men often have reduced bone mineral density (BMD) at diagnosis because testosterone and its estradiol metabolite are essential for peak bone mass accrual, which continues until approximately age 30 [13]. A dual-energy X-ray absorptiometry (DXA) scan at baseline is reasonable for men under 30 with confirmed hypogonadism. Testosterone therapy, when dosed appropriately, has been shown to increase lumbar spine and hip BMD in hypogonadal men over 12 to 24 months [14].

Cardiovascular Risk: What the Evidence Actually Shows

Cardiovascular safety of testosterone therapy in young men is an area of genuine uncertainty. In 2015, the FDA required all testosterone products, including AndroGel, to carry a label warning about a possible increased risk of myocardial infarction and stroke based on observational data and two earlier studies [15]. The label was not a contraindication, it was a precautionary signal requiring individualized assessment.

The TRAVERSE trial (N=5,246, mean age 65.6 years) published in the New England Journal of Medicine in 2023 found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median 33 months of follow-up, with a hazard ratio of 0.96 (95% CI 0.78, 1.17) [16]. TRAVERSE enrolled older men with pre-existing cardiovascular disease or high risk, so its reassurance has limits when extrapolated to healthy 25-year-olds. Nonetheless, it substantially lowered concern about a dramatic short-term MACE risk from testosterone.

For young adults specifically, the major cardiovascular concerns are:

1. Erythrocytosis. Testosterone stimulates erythropoiesis. Hematocrit above 54% increases blood viscosity and thrombotic risk. The Endocrine Society guideline recommends withholding or reducing testosterone if hematocrit exceeds 54% [8].
2. Dyslipidemia. Testosterone reduces HDL cholesterol, sometimes by 10 to 15% [17]. Young men with familial hypercholesterolemia or other lipid disorders need close monitoring.
3. Sleep apnea. Testosterone can worsen obstructive sleep apnea, which in turn strains cardiac function. Screen for symptoms at every follow-up visit.

Baseline cardiovascular assessment should include blood pressure, fasting lipids, hematocrit, and a review of personal and family cardiac history before the first AndroGel prescription in a young adult.

Skin Transfer: A Specific Risk for Young Patients

Young men are more likely to live with or have frequent physical contact with children, female partners, or infants compared with older patients. Testosterone gel transfers readily from treated skin to another person's skin during direct contact, and transferred testosterone can cause virilization in women and premature puberty in children [18].

The FDA mandates patient counseling on gel transfer with every testosterone gel prescription [15]. Practical steps include:

• Apply AndroGel only to shoulders and upper arms (not the abdomen, per the 1.62% formulation label).
• Wash hands with soap and water immediately after application.
• Cover the application site with clothing before any skin-to-skin contact.
• Shower before close contact if gel was applied hours earlier and the site was not covered.

A 2010 FDA Public Health Advisory documented cases of premature sexual development in children who were exposed to testosterone gel via skin contact with adult male household members [19]. The risk is real and dose-dependent.

Psychological and Behavioral Considerations in Young Adults

Testosterone influences mood, aggression, libido, and risk-taking behavior. Young men in the 18, 29 age range already have relatively high endogenous testosterone compared with older populations, and the interaction between exogenous testosterone and developing adult behavior patterns deserves clinical attention.

Supraphysiologic serum T levels, which can result from excessive dosing or suboptimal monitoring, are associated with increased irritability and, in some individuals, mood instability [20]. Keeping serum T within the mid-normal range for age (roughly 400 to 700 ng/dL on a morning draw) minimizes this risk. Dose adjustments based on trough levels, measured two weeks after initiation or any dose change, keep levels predictable.

Young men are also at higher risk for misuse or dose escalation than older patients. Testosterone is a Schedule III controlled substance under the Controlled Substances Act [21]. Prescribers should document the medical indication clearly, avoid early refills, and re-evaluate the diagnosis at each annual visit.

Anabolic steroid misuse at supraphysiologic doses (far above what AndroGel delivers at standard doses) is associated with adverse cardiac remodeling, hepatotoxicity with oral androgens, and severe HPG suppression [22]. Standard AndroGel dosing does not carry these risks, but the distinction should be explained to young patients who may have encountered messaging about performance-enhancing steroid use.

Dosing Protocol for Young Adults

The FDA-approved starting dose of AndroGel 1.62% is 40.5 mg (2 pump actuations) applied once daily to the shoulders and upper arms. Dose titration is based on serum testosterone measured two weeks after starting or after any dose change, collected as a morning sample (ideally 8 to 10 a.m.) approximately two hours after gel application [2].

Target range is 400 to 700 ng/dL for most young hypogonadal men, though some clinicians target the lower half of the normal range initially to assess tolerability and minimize suppression of residual endogenous function. The maximum approved dose for AndroGel 1.62% is 81 mg (4 actuations) daily.

Dose titration schedule:

• If T is below 350 ng/dL at the 2-week check, increase by one actuation (20.25 mg).
• If T is above 750 ng/dL, decrease by one actuation.
• Recheck at 6 weeks post-titration, then at 3 months, 6 months, and annually [8].

Missing doses disrupts the steady-state serum T level. Young adults with active, variable schedules should apply gel at the same time each morning, ideally after showering, to build the habit and avoid accidental transfer to others.

Monitoring Schedule: What Labs, When, and Why

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies the following monitoring schedule for men on testosterone therapy [8]:

• 3 months: Serum total testosterone (morning), hematocrit, PSA (if baseline PSA was checked), symptom review.
• 6 months: Repeat all above plus fasting lipid panel and blood pressure.
• 12 months and annually: All above plus DXA if baseline BMD was low, and re-evaluation of fertility intentions for young patients.
• LH and FSH at 6 months: Confirms HPG suppression; unexpected persistence of normal LH may indicate non-adherence or poor absorption.

A hematocrit above 54% at any point requires dose reduction or temporary discontinuation [8]. The FDA label also advises monitoring for signs of benign prostatic hyperplasia and for polycythemia [15]. PSA elevation above 1.4 ng/mL per year or above 4 ng/mL in absolute terms warrants urological referral, even in young adults, though prostate cancer at age 18, 29 is exceedingly rare [23].

Liver function testing is not routinely required for gel formulations because topical testosterone bypasses hepatic first-pass metabolism, unlike oral 17-alpha alkylated androgens [24].

Transferring Off AndroGel: Stopping, Switching, and Recovery

Young men may want to stop AndroGel at some point, whether for fertility planning, side effect management, or a change in lifestyle. Abrupt discontinuation is safe from a medical standpoint but often causes a return of hypogonadism symptoms within one to four weeks as exogenous testosterone clears and endogenous production remains suppressed.

For men with secondary hypogonadism (low LH and FSH at baseline), a structured restart protocol using clomiphene citrate 25 mg daily or every other day, or hCG 1,000, 2 to 000 IU every other day for six to eight weeks, may help reactivate the HPG axis more quickly after stopping testosterone [25]. Recovery of endogenous T production is more likely in secondary hypogonadism than in primary, where Leydig cell function is intrinsically impaired.

Sperm count recovery after stopping AndroGel generally begins within three to six months but may take up to 24 months to reach pre-treatment levels, if it occurs at all [6]. Men planning to conceive should ideally stop testosterone therapy at least six months before attempting conception and recheck semen analysis to confirm recovery.

What the Endocrine Society Actually Says

The Endocrine Society's 2018 guideline states directly: "We suggest against starting testosterone therapy in patients who are currently desiring fertility" [8]. The same guideline notes that testosterone therapy may be offered to men with documented hypogonadism after a full discussion of expected benefits and risks, including the fertility concern. The American Urological Association's 2018 guideline for evaluation and management of testosterone deficiency echoes that recommendation and adds that all men should be counseled about the fertility risk before initiating any form of testosterone therapy [26].

Neither guideline categorically excludes men aged 18, 29. Both require evidence of two low morning testosterone readings, clinical symptoms, and documentation of the informed consent discussion before prescribing begins.

Secondary Hypogonadism in Young Men: Rule Out the Cause First

Young men diagnosed with secondary hypogonadism (low T plus low or inappropriately normal LH and FSH) need a pituitary MRI and prolactin level before starting lifelong testosterone replacement [3]. A prolactin-secreting adenoma (prolactinoma) is the most common pituitary tumor in adults under 40 and is a treatable cause of secondary hypogonadism [27]. Treating the prolactinoma with cabergoline, a dopamine agonist, often restores normal testosterone and spermatogenesis without any testosterone replacement at all.

Starting AndroGel before ruling out a prolactinoma masks the underlying pathology, delays appropriate treatment, and commits the patient to exogenous testosterone unnecessarily. A single serum prolactin measurement and a pituitary MRI with contrast cost far less than decades of AndroGel and its associated monitoring burden.

Genetic testing for Klinefelter syndrome should be considered in young men with primary hypogonadism, small firm testes, and an elevated FSH, especially if they have not had a prior karyotype [4].